Carasent

Earnings Release • May 15, 2019

APPTIX ASA

Quarterly Presenta-on Q1 2019 May 15

Q1 2019 Highlights

• Evimeria EMR AB shows con3nued strong growth and profitability for the first quarter and are well in line with targets for 2019.
• Overview of First Quarter 2019 results for Evimeria EMR AB (in SEK and Swedish GAAP)
• Revenue of SEK 13,5 million, an increase of 46 % as compared to Q1 2018
• EBITDA of SEK 3,4 million as compared to SEK 2,0 million during Q1 2018.
• EBIT of SEK 2,5 million as compared to SEK 1,5 million during Q1 2018.
• Signed 21 new clinics during the First Quarter 2019, which is higher than previous year represen3ng more than one new clinic per week. Ended the first quarter with 336 ac3ve clinics.
• Market condi3ons remains strong within all targeted segments, including expansion into occupa3onal health services.

Q1 2019 Financials

.

• Revenue for the first quarter of 2019 totaled NOK 11,1 million as compared to no revenues during the first quarter 2018. All revenues are related to Evimeria EMR AB.
• OperaEng expenses for the first quarter of 2019 totaled NOK 7,2 million as compared NOK 3,0 million during the first quarter of 2018. OperaEng expenses excludes cost of sales and amorEzaEons.
• NOK 6,6 million of the operaEng expenses for the first quarter of 2019 relates to Evimeria EMR AB. NOK 0,6 million consists of professional fees (legal, accounEng and consulEng) along with public Company costs such as stock exchange registraEon, insurance and board remuneraEon fees.
• Net profit for the first quarter of 2019 totaled NOK 1,0 million as compared to a net loss of NOK 3,0 million during the first quarter of 2018.
• The Company ended the first quarter of 2019 with NOK 7,2 million of available cash balances and outstanding debt of NOK 2,9 million (not including lease liability)

¢ CARASENT

New name - CARASENT ASA

• · www.carasent.com
• New ticker: CARA
• Effective within the next week

New contract with doktor.se

• On April 15th Evimeria EMR AB signed a contract with doktor.se, a leading Swedish online-doctor.
• Important breakthrough with a wellknown provider in this fast growing market segment.
• The contract value is iniEally approx. SEK 2 million per year and doctor.se will be one of Evimeria biggest customers so far.

– "Vi har Sveriges populäraste vårdapp och vill effek9visera svensk sjukvård. Därför har vi fokuserat på a@ hi@a en journalpartner som klarar av a@ fortsä@a utveckla sin produkt i takt med a@ vår verksamhet förändras, och det gör Evimeria. Vi ser fram emot a@ komma igång med samarbetet, säger Mar9n Lindman, VD på Doktor.se"

Reversed split

• The company currently has 162,535,285 issued shares, par value NOK 0.333 each.
• The Board of Directors is of the view that a merger (reverse split) of the company's shares, implying an increase of the shares' par value, is in the company's and the shareholders' interest.
• The Board of Directors proposes to the general meeHng to change the par value such that 4 shares is merged into 1.
• Following approval on the general meeHng the change will be effecHve within the next week.

Outlook and targets

• Evimeria EMR AB is well in line with targets for 2019
• More than one new clinic per week
• 50% revenue growth
• Double EBITDA
• Carasent ASA
• AcFvely searching to expand its geographical and/or service offering through partnerships or acquisiFons within the healthtech segment